These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37856198)

  • 1. Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.
    Stabellini N; Cao L; Towe CW; Miller ME; Sousa-Santos AH; Amin AL; Montero AJ
    J Natl Compr Canc Netw; 2023 Oct; 21(10):1011-1019.e6. PubMed ID: 37856198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
    van Maaren MC; van Steenbeek CD; Pharoah PDP; Witteveen A; Sonke GS; Strobbe LJA; Poortmans PMP; Siesling S
    Eur J Cancer; 2017 Nov; 86():364-372. PubMed ID: 29100191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients.
    Zaguirre K; Kai M; Kubo M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Morisaki T; Mori H; Oda Y; Chen S; Moriyama T; Shimizu S; Nakamura M
    Cancer Med; 2021 Mar; 10(5):1605-1613. PubMed ID: 33452761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis.
    Tamirisa N; Lin H; Shen Y; Shaitelman SF; Karuturi MS; Giordano SH; Babiera GV; Bedrosian I
    Cancer; 2021 Jul; 127(13):2196-2203. PubMed ID: 33735487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer.
    Veitch Z; Khan OF; Tilley D; Ribnikar D; Kostaras X; King K; Tang P; Lupichuk S
    J Natl Compr Canc Netw; 2019 Jan; 17(1):47-56. PubMed ID: 30659129
    [No Abstract]   [Full Text] [Related]  

  • 8. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
    Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
    Engelhardt EG; van den Broek AJ; Linn SC; Wishart GC; Rutgers EJT; van de Velde AO; Smit VTHBM; Voogd AC; Siesling S; Brinkhuis M; Seynaeve C; Westenend PJ; Stiggelbout AM; Tollenaar RAEM; van Leeuwen FE; van 't Veer LJ; Ravdin PM; Pharaoh PDP; Schmidt MK
    Eur J Cancer; 2017 Jun; 78():37-44. PubMed ID: 28412587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population-based validation of the prognostic model PREDICT for early breast cancer.
    Wishart GC; Bajdik CD; Azzato EM; Dicks E; Greenberg DC; Rashbass J; Caldas C; Pharoah PD
    Eur J Surg Oncol; 2011 May; 37(5):411-7. PubMed ID: 21371853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.
    Park S; Lee SK; Paik HJ; Ryu JM; Kim I; Bae SY; Yu J; Kim SW; Lee JE; Nam SJ
    Medicine (Baltimore); 2017 Jun; 96(22):e6777. PubMed ID: 28562530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry.
    Wijeratne DT; Gunasekera S; Booth CM; Promod H; Jalink M; Jayarajah U; Seneviratne S
    BMC Cancer; 2021 Nov; 21(1):1175. PubMed ID: 34732162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
    Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
    Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
    Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
    Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
    Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
    Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M;
    Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.